Research

Texas Therapeutics Institute

The Texas Therapeutics Institute at The Brown Foundation Institute of Molecular Medicine (TTI-IMM) was established in 2010 by Dr. C. Thomas Caskey with funding from the Texas Emerging Technology Fund, The University of Texas System, and The University of Texas Health Science Center at Houston. TTI-IMM was created for the discovery, development, and commercialization of therapeutic agents and diagnostic tools. Research conducted at the center focuses on the establishment of proof-of-principle for therapeutics and the identification and validation of drug targets. TTI is located in the Fayez S. Sarofim Research Building, in the heart of the Texas Medical Center. TTI’s mission is to carry out translational research and drug discoveries related to cancer, cardiovascular disease, and stem cells.

Read about the Texas Therapeutics Institute

CPRIT Therapeutic Antibody Discovery Core

We offer Texas-wide access to specialized technical expertise, instrumentation, and automation to advance lead antibodies with “drug like” properties from academic laboratories to the stage of preclinical development.

Read about Antibody Discovery

Preclinical Development Core for Large Molecule Therapeutics

Large molecule therapeutics, such as antibodies and other protein-based drugs, has become the major modality of oncology treatments. Discovery and development of drug candidates require detailed characterization of the candidates in pharmacokinetics (PK) and potential toxicity (Tox, also known as safety assessment) in designated animal species, a process called preclinical development. Understanding of PK and Tox is essential for the advancement of the candidates into clinical trials.

Read about Preclinical Development